Pharmaceuticals Acquisitions in 2022
-
- Buyer
- Advent International
- Target
- Suven Pharmaceuticals
- Seller
- Jasti family
- Industry
- Pharmaceuticals
- Location
- Telangana, India
- Type
- Buyout
Advent International has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family and will make an open offer for an additional 26% of public shares. Advent plans to evaluate a merger of its CDMO and API platform company, Cohance Lifesciences, with Suven to create a scaled end-to-end CDMO + merchant API powerhouse serving pharma and specialty chemical markets, subject to board and regulatory approvals.
-
December 20, 2022
- Buyer
- KKR
- Target
- Bushu Pharmaceuticals
- Seller
- BPEA V Fund (BPEA EQT)
- Industry
- Pharmaceuticals
- Location
- Saitama, Japan
- Type
- Buyout
KKR has agreed to acquire Bushu Pharmaceuticals, a leading Japanese pharmaceutical CDMO headquartered in Kawagoe, from the BPEA V Fund (BPEA EQT). Bushu operates four manufacturing facilities across Japan, employs around 1,600 people, and provides contract development and manufacturing services for pharmaceuticals and medical devices; the deal is expected to close in Q1 2023 subject to customary approvals.
-
- Buyer
- Essential Pharma, Gyrus Capital
- Target
- HALDOL (haloperidol), HALDOL Decanoate (haloperidol decanoate)
- Seller
- Janssen Pharmaceutica NV
- Industry
- Pharmaceuticals
- Location
- Antwerp, Belgium
- Type
- Divestiture
Gyrus Capital-backed Essential Pharma has acquired global rights to HALDOL (haloperidol) and HALDOL Decanoate from Janssen Pharmaceutica NV. The deal expands Essential Pharma's specialty CNS portfolio and secures continued global supply of this WHO-listed essential antipsychotic marketed in the US and more than 60 countries.
-
November 17, 2022
- Buyer
- Biocodex Group
- Target
- Hilma
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
French pharmaceutical group Biocodex has acquired a majority stake in Hilma, a U.S.-based natural remedies start-up founded by Hilary Quartner, Nina Mullen and Lily Galef. The deal gives Biocodex a stronger foothold in the U.S. digestive-health and women’s-health segments and will help scale Hilma’s omnichannel retail strategy (DTC plus 750+ stores including Target).
-
November 16, 2022
- Buyer
- The Riverside Company
- Target
- BioDue S.p.A
- Seller
- Benedetti family / existing management (re-investing alongside Riverside)
- Industry
- Pharmaceuticals
- Location
- Tuscany, Italy
- Type
- Buyout
The Riverside Company has signed a definitive agreement to acquire a controlling stake in BioDue S.p.A, an Italian developer and manufacturer of dietary supplements, medical devices and cosmetics. Riverside plans to pursue a pan‑European buy‑and‑build strategy to expand BioDue's product range and commercial reach, while supporting operational improvements across its production sites.
-
November 14, 2022
- Buyer
- Indivior PLC
- Target
- Opiant Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Indivior PLC will acquire Opiant Pharmaceuticals, Inc. for $20.00 per share in cash (approximately $145 million aggregate) plus up to $8.00 per share in contingent value rights tied to OPNT003 revenue milestones. The acquisition strengthens Indivior's addiction-treatment portfolio by adding Opiant's OPNT003 intranasal opioid overdose candidate and earlier-stage pipeline assets, and is expected to be accretive after the second full year of OPNT003 launch.
-
- Buyer
- NB Renaissance, Ardian
- Target
- Neopharmed Gentili
- Seller
- Del Bono family, Mediolanum Farmaceutici, Ardian
- Industry
- Pharmaceuticals
- Location
- Italy
- Type
- Buyout
NB Renaissance won a beauty contest to partner with Ardian and acquire majority ownership of Italian pharmaceutical group Neopharmed Gentili via a 50/50 vehicle, valuing the company at about €1.4–1.5 billion. The Del Bono family (through Mediolanum Farmaceutici) will retain a minority stake while Ardian will sell its existing stake into the vehicle and reinvest alongside NB Renaissance to hold half of the vehicle.
-
November 9, 2022
- Buyer
- Ascensus Specialties LLC
- Target
- Strem Chemicals UK (Strem UK)
- Industry
- Pharmaceuticals
- Location
- England, United Kingdom
- Type
- Buyout
Ascensus Specialties LLC acquired the business and certain assets of Strem Chemicals UK (Strem UK), the independent UK distributor of Ascensus high‑purity research reagents and CVD/ALD precursors. The deal brings Strem UK’s customer relationships into Ascensus’ global distribution footprint, with Strem UK senior leadership remaining to support a smooth transition.
-
October 31, 2022
- Buyer
- TPG (TPG Capital Asia), Pacific Equity Partners
- Target
- iNova Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- Singapore
- Type
- Buyout
TPG (through its Asia platform) completed a majority investment in iNova Pharmaceuticals, a multinational consumer health and pharmaceutical company, with existing investor Pacific Equity Partners re-investing as a minority co-investor. The deal will support iNova's regional expansion and growth strategy across Southeast and North Asia, and fund channel expansion, product-in-fill and technology investments.
-
October 25, 2022
- Buyer
- Symeres, Keensight Capital
- Target
- Exemplify BioPharma
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Addon
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
-
October 20, 2022
- Buyer
- Sunshine Biopharma Inc.
- Target
- Nora Pharma Inc.
- Industry
- Pharmaceuticals
- Location
- Quebec, Canada
- Type
- Buyout
Sunshine Biopharma Inc. has completed the acquisition of all outstanding shares of Nora Pharma Inc., making Nora Pharma a wholly owned subsidiary. The deal (C$30.0 million) expands Sunshine’s business into generic prescription drugs, over‑the‑counter products and biosimilars and adds approximately $10.7 million in revenue and 36 employees based in the Greater Montreal area.
-
October 20, 2022
- Buyer
- Webster Equity Partners, Gurnet Point Capital
- Target
- Corium Pharma Solutions (manufacturing business), Corium (neuroscience therapeutics commercialization business)
- Seller
- Corium, LLC
- Industry
- Pharmaceuticals
- Location
- Michigan, United States
- Type
- Divestiture
Webster Equity Partners and Gurnet Point Capital have acquired Corium's manufacturing business (now Corium Pharma Solutions) in a transaction valuing the CDMO at more than $400 million, while Webster also made a concurrent $100 million equity investment in Corium's neuroscience commercialization business. The deal splits Corium into two independent companies — a CDMO and a neuroscience therapeutics commercialization company — with Gurnet Point and Webster jointly owning the CDMO and holding board representation in both businesses.
-
October 3, 2022
- Buyer
- Incyte
- Target
- Villaris Therapeutics, Auremolimab (VM6)
- Industry
- Pharmaceuticals
- Location
- North Carolina, United States
- Type
- Buyout
Incyte has entered into an agreement to acquire Villaris Therapeutics, a Medicxi-backed biopharmaceutical focused on vitiligo. Incyte will pay $70 million upfront and provide potential additional milestone payments of up to $1.36 billion for auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody.
-
October 3, 2022
- Buyer
- Aspire Pharma, H.I.G. Capital
- Target
- Morningside Healthcare, Morningside Pharmaceuticals
- Seller
- Shareholders of Morningside
- Industry
- Pharmaceuticals
- Location
- Leicestershire, United Kingdom
- Type
- Addon
Aspire Pharma, a portfolio company of H.I.G. Capital, has acquired Morningside Healthcare and Morningside Pharmaceuticals, a UK provider of niche generic and branded specialty medicines. The deal (terms undisclosed) will combine the companies’ complementary product portfolios to expand scale, accelerate product development and support international growth and further M&A.
-
September 30, 2022
- Buyer
- Zoetis Inc.
- Target
- Jurox
- Seller
- O'Brien family
- Industry
- Pharmaceuticals
- Location
- New South Wales, Australia
- Type
- Buyout
Zoetis Inc. has completed its acquisition of Jurox, a privately held Australian animal health company that develops, manufactures and markets veterinary medicines, including the anaesthetic Alfaxan. The deal expands Zoetis' veterinary product portfolio and manufacturing capabilities in Australia and supports greater global distribution of Jurox products.
-
September 16, 2022
- Buyer
- JanOne Inc.
- Target
- Soin Therapeutics LLC
- Industry
- Pharmaceuticals
- Location
- Ohio, United States
- Type
- Buyout
JanOne Inc. has executed a term sheet to acquire Soin Therapeutics LLC and its patent-pending low-dose naltrexone formulation (to be named JAN123) for the treatment of Complex Regional Pain Syndrome (CRPS). The deal is valued at $13 million up front with up to $17 million in additional contingent payments (total up to $30 million); JanOne expects to advance JAN123 into GMP manufacturing and file an IND in 2023.
-
September 14, 2022
- Buyer
- Everstone Capital
- Target
- Softgel Healthcare Private Limited
- Seller
- Madras Pharma Group, A. M. Sulaiman
- Industry
- Pharmaceuticals
- Location
- Tamil Nadu, India
- Type
- Buyout
Everstone Capital has acquired a controlling (majority) stake in Softgel Healthcare Private Limited (SHPL), a Chennai-headquartered CDMO specializing in soft gelatin capsules and probiotics and part of the Madras Pharma Group. The investment will support SHPL's global expansion and capability development across pharmaceutical, nutraceutical and OTC markets, with Everstone partners joining the company's board.
-
September 10, 2022
- Buyer
- BPOC (Beecken Petty O'Keefe & Company)
- Target
- Praxis Packaging Solutions
- Seller
- Huizenga Group
- Industry
- Pharmaceuticals
- Location
- Michigan, United States
- Type
- Growth capital
Chicago-based healthcare investor BPOC (Beecken Petty O’Keefe & Company) made a strategic minority/majority investment in Praxis Packaging Solutions, a Grand Rapids-based contract packaging provider for OTC/Rx pharmaceuticals, medical devices, animal health and health & beauty products. Huizenga Group will retain a minority stake; proceeds will fund expanded sales and marketing and broadened service capabilities, and John Lowry will join Praxis as Executive Chairman.
-
September 7, 2022
- Buyer
- SK Capital Partners, Comvest Partners
- Target
- VanDeMark Chemical, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
Funds advised by SK Capital Partners have made a strategic investment in VanDeMark Chemical, a Comvest Partners portfolio company headquartered in Lockport, New York. Comvest remains a co-owner; the investment will accelerate VanDeMark's growth and deepen its focus on life-science specialty chemistries, with SK Capital supporting organic and inorganic expansion.
-
September 7, 2022
- Buyer
- eMolecules, Inc., Avista Capital Partners
- Target
- Frontier Scientific Inc., Frontier Agricultural Sciences Inc.
- Industry
- Pharmaceuticals
- Location
- Delaware, United States
- Type
- Addon
eMolecules, a PE-backed provider of a chemistry search-and-fulfillment platform, has acquired Frontier Scientific Inc. (FSI) and Frontier Agricultural Sciences Inc. (FAS). The acquisitions expand eMolecules' capabilities in compound/sample management, analytical and procurement services and provide an entry into agricultural chemistry/entomology research markets.
-
September 1, 2022
- Buyer
- Permira (funds advised by Permira), Marcucci family, Abu Dhabi Investment Authority (ADIA) - via a wholly-owned subsidiary, Ampersand Capital Partners
- Target
- Kedrion Biopharma, Bio Products Laboratory (BPL)
- Industry
- Pharmaceuticals
- Location
- Tuscany, Italy
- Type
- Buyout
Funds advised by Permira, in partnership with the Marcucci family and supported by a subsidiary of ADIA and Ampersand Capital Partners, completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL) to create a global leader in plasma derivatives and rare disease medicines. The combined company will be headquartered in Italy, generate over €1.1 billion in revenue, and expand its global footprint (including a ~75 US plasma center footprint); Ugo Di Francesco has been appointed CEO effective January 2023.
-
September 1, 2022
- Buyer
- Novo Nordisk
- Target
- Forma Therapeutics, Holdings Inc.
- Industry
- Pharmaceuticals
- Location
- United States
- Type
- Buyout
Novo Nordisk will acquire Forma Therapeutics in a cash tender offer at $20 per share, valuing the deal at about $1.1 billion. The acquisition is intended to expand Novo Nordisk’s scientific and pipeline presence in sickle cell disease and other rare blood disorders, including Forma’s lead candidate etavopivat.
-
August 22, 2022
- Buyer
- LTS LOHMANN Therapie-Systeme AG
- Target
- Tapemark Inc.
- Industry
- Pharmaceuticals
- Location
- Minnesota, United States
- Type
- Buyout
LTS LOHMANN Therapie-Systeme AG (LTS) has completed the acquisition of Tapemark Inc., a U.S.-based CDMO specializing in transdermal drug delivery systems and oral thin films. The deal integrates Tapemark’s St. Paul (West St. Paul), Minnesota facility into LTS’s global network to strengthen LTS’s U.S. footprint, expand manufacturing capacity and R&D capabilities, and broaden its drug-delivery technology portfolio.
-
August 12, 2022
- Buyer
- Ipsen
- Target
- Epizyme, Inc. (Epizyme)
- Seller
- Royalty Pharma (support agreement; agreed to tender shares)
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.
-
August 11, 2022
- Buyer
- Edgewater Capital Partners
- Target
- GL CHEMTEC
- Industry
- Pharmaceuticals
- Location
- Ontario, Canada
- Type
- Buyout
Edgewater Capital Partners, a Cleveland-based lower middle-market private equity firm, has acquired GL CHEMTEC, a chemistry-based contract research organization (CRO) headquartered in Oakville, Ontario. Edgewater will support GLC's expansion of API development, scale-up and advanced materials capabilities to accelerate growth across North American pharma and life-sciences customers.
-
August 2, 2022
- Buyer
- Adalvo
- Target
- Onsolis
- Industry
- Pharmaceuticals
- Location
- United States
- Type
- Divestiture
Adalvo has acquired full global rights to the branded opioid analgesic Onsolis from a U.S.-based specialty pharmaceutical owner, becoming the sole and exclusive owner of the product and assuming supply and market authorisation responsibilities worldwide. The product, indicated for management of breakthrough cancer pain in opioid-tolerant patients, is sold in several EU countries and Taiwan and Adalvo intends to integrate it into its expanding branded-product portfolio.
-
August 1, 2022
- Buyer
- Arecor Therapeutics
- Target
- Tetris Pharma Limited
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Type
- Buyout
Xeris Biopharma announced that its commercialization partner Tetris Pharma Limited will be acquired by Arecor Therapeutics, contingent on a successful capital offering. Arecor would continue to commercialize Ogluo (glucagon) in the United Kingdom and the European Economic Area (EEA), maintaining Tetris’s commercialization role under the existing partnership framework.
-
- Buyer
- ANI Pharmaceuticals, Inc.
- Target
- Four ANDAs (from Oakrum Pharma, LLC)
- Seller
- Oakrum Pharma, LLC
- Industry
- Pharmaceuticals
- Location
- Missouri, United States
- Type
- Divestiture
ANI Pharmaceuticals, Inc. acquired four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC in an asset purchase announced July 28, 2022. The acquisition expands ANI's generics product portfolio and is intended to enable product launches and revenue contribution beginning in 2023.
-
July 27, 2022
- Buyer
- Italfarmaco
- Target
- Lacer Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- Spain
- Type
- Buyout
Italfarmaco acquired 100% of Lacer Pharmaceuticals, a leading Spanish health and personal hygiene company focused on oral/dental and other therapeutic areas. The deal is subject to competition authorities’ approval and is expected to strengthen Italfarmaco’s presence in Spain and enable international growth for Lacer’s brands.
-
July 11, 2022
- Buyer
- Innoviva, Inc., Innoviva (wholly owned subsidiary)
- Target
- La Jolla Pharmaceutical Company
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Innoviva entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for $6.23 per share in cash (including a tender offer), representing an implied enterprise value of about $149 million. The acquisition adds GIAPREZA and XERAVA to Innoviva’s infectious disease and hospital portfolio and was completed in August 2022, with La Jolla becoming a wholly owned subsidiary and delisted from Nasdaq.
-
- Buyer
- BroadOak Capital Partners, Investor group of industry veterans (including Derek Hennecke and TJ Higley)
- Target
- Microsize
- Seller
- Lonza
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Type
- Divestiture
BroadOak Capital Partners led an investor-backed launch of Microsize after acquiring Lonza’s North American micronization business in Quakertown, Pennsylvania. The newly independent CDMO — operating three facilities and focused on micronization and particle-size control for APIs and excipients — will be run by industry veterans including Chairman Derek Hennecke and CEO TJ Higley to expand US-based API solubility and bioavailability enhancement capabilities.
-
- Buyer
- TPG Capital
- Target
- Diocle Topco S.àr.l. (parent of DOC Generici)
- Seller
- ICG, Mérieux Equity Partners
- Industry
- Pharmaceuticals
- Location
- Lombardy, Italy
- Type
- Buyout
TPG Capital has signed a definitive agreement to acquire a majority interest in Diocle Topco S.àr.l., the parent company of DOC Generici, from ICG and Mérieux Equity Partners. DOC Generici is a leading Italian manufacturer of generic pharmaceuticals based in Milan; TPG said it will partner with management to pursue organic and inorganic growth in the Italian generics market.
-
- Buyer
- Altaris Capital Partners, LLC
- Target
- Veranova (formerly Johnson Matthey's Health business)
- Seller
- Johnson Matthey PLC
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Type
- Buyout
Altaris Capital Partners completed the acquisition of Veranova (formerly Johnson Matthey's Health business) from Johnson Matthey PLC for total consideration of up to £325 million, with Johnson Matthey retaining approximately a 30% equity stake. Veranova is a global CDMO focused on specialty and complex active pharmaceutical ingredients (APIs), headquartered in Wayne, Pennsylvania, with roughly 900 employees across seven development and manufacturing sites in North America, Europe and Asia.
-
May 24, 2022
- Buyer
- ARCHIMED, Caisse de dépôt et placement du Québec (CDPQ)
- Target
- Corealis Pharma
- Industry
- Pharmaceuticals
- Location
- Quebec, Canada
- Type
- Recapitalization
Transatlantic PE firm ARCHIMED, joined by Caisse de dépôt et placement du Québec (CDPQ), has recapitalized Corealis Pharma, a Laval, Quebec–based CDMO specializing in oral solid dosage formulation and clinical-supply manufacturing. The recapitalization will fund expansion of GMP-compliant facilities, R&D capabilities and accelerate growth for Corealis to serve small- and mid-sized biotech and pharma customers.
-
- Buyer
- Mirum Pharmaceuticals, Inc.
- Target
- Satiogen Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) acquired San Diego-based Satiogen Pharmaceuticals, obtaining Satiogen-owned IP and licensing payments related to LIVMARLI (maralixibat) and volixibat. The deal, funded via Mirum stock and roughly $2.8 million in cash, reduces Mirum's royalty obligations and consolidates the economics of its commercial and pipeline programs.
-
- Buyer
- Alcon Inc.
- Target
- Kala Pharmaceuticals, Inc.
- Seller
- Kala Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.
-
- Buyer
- Taiho Pharmaceutical Co., Ltd.
- Target
- Cullinan Pearl Corp.
- Seller
- Cullinan Oncology, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Taiho Pharmaceutical Co., Ltd. will acquire Cullinan Pearl Corp., a subsidiary of Cullinan Oncology, for $275 million upfront plus up to $130 million in regulatory milestone payments, and will co-develop and co-commercialize CLN-081/TAS6417. Cullinan Oncology will retain co-development and an option to co-commercialize in the U.S.; the deal provides Cullinan Oncology with cash to extend its runway and reduces its development and pre-commercialization costs.
-
- Buyer
- Aztiq Pharma Partners, Innobic (Asia) Company Limited, Aztiq II HoldCo (consortium)
- Target
- Alvogen Emerging Markets Holdings Limited (AEMH), Lotus Pharmaceutical Co., Ltd. (Lotus), Adalvo
- Seller
- Alvogen Lux Holdings Sarl (Alvogen), Existing shareholders of AEMH
- Industry
- Pharmaceuticals
- Location
- Malta
- Type
- Buyout
Aztiq Pharma Partners (led by Róbert Wessman) and Innobic (Asia) Company Limited, through Aztiq II HoldCo, completed a $500 million acquisition of 100% of Alvogen Emerging Markets Holdings Limited (AEMH). The deal makes the consortium the leading shareholder in Lotus Pharmaceuticals and the owner of Alvogen Malta Holding Ltd. (the shareholder of Adalvo), positioning the group to expand pharmaceutical capabilities and commercial reach—particularly across ASEAN markets.
-
- Buyer
- Astorg
- Target
- CordenPharma
- Seller
- International Chemical Investors Group (ICIG)
- Industry
- Pharmaceuticals
- Location
- Basel-Stadt, Switzerland
- Type
- Buyout
Astorg has signed a binding agreement to acquire CordenPharma, a global contract development and manufacturing organization (CDMO) focused on APIs, excipients and drug products, from International Chemical Investors Group (ICIG). CordenPharma employs over 2,600 people across 11 manufacturing sites and an R&D laboratory in Europe and the US; the founders will reinvest alongside Astorg. The transaction is subject to customary regulatory approvals and terms were not disclosed.
-
- Buyer
- Bonafide Health
- Target
- MSI-195 (enhanced SAM-e formulation) / Methylation Sciences (MSI)
- Seller
- Methylation Sciences International (MSI)
- Industry
- Pharmaceuticals
- Location
- British Columbia, Canada
- Type
- Buyout
Bonafide Health has acquired worldwide rights and all assets related to MSI-195, a patented high-bioavailability formulation of S-adenosylmethionine (SAM-e). The acquisition expands Bonafide’s patented ingredient portfolio and strengthens its R&D pipeline for next-generation women’s health and dietary supplement products.
-
April 19, 2022
- Buyer
- Consegna Pharma Inc.
- Target
- Fathom Pharma LLC
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Type
- Buyout
Consegna Pharma Inc. has acquired Fathom Pharma LLC, making Fathom a wholly owned subsidiary to strengthen Consegna's long-acting injectable (LAI) portfolio and initiatives addressing the opioid crisis. The acquisition is intended to accelerate clinical development of long-acting pain therapeutics that are designed to be less susceptible to abuse or diversion.
-
April 13, 2022
- Buyer
- Halozyme Therapeutics, Inc.
- Target
- Antares Pharma, Inc.
- Seller
- Antares shareholders
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Halozyme Therapeutics will acquire Antares Pharma for $5.60 per share in cash, valuing Antares at approximately $960 million. The deal, approved unanimously by both boards, is intended to expand Halozyme's drug delivery capabilities by adding Antares' auto-injector platform and commercial specialty products and is expected to be accretive to Halozyme's 2022 revenue and non-GAAP earnings.
-
April 6, 2022
- Buyer
- Alter Pharma, The Riverside Company
- Target
- EcoPharmaSupply (EPS)
- Industry
- Pharmaceuticals
- Location
- Hainaut, Belgium
- Type
- Addon
Belgian pharmaceutical group Alter Pharma — a Riverside-backed platform — has acquired EcoPharmaSupply (EPS), a Benelux-focused pharmaceutical distributor and services company. The add-on expands Alter Pharma’s distribution footprint, product portfolio (OTC, consumer health, medical devices and prescription drugs) and logistics/procurement capabilities to support pharmacy and hospital customers in the Benelux region.
-
- Buyer
- Bruker Corporation
- Target
- Optimal Industrial Automation and Technologies (Optimal)
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Type
- Buyout
Bruker Corporation acquired UK-based Optimal Industrial Automation and Technologies, a provider of pharma and biopharma process analytical technology (PAT), manufacturing automation and QA software (including the synTQ platform). The acquisition strengthens Bruker's biopharma manufacturing automation and PAT software capabilities to complement its instrumentation portfolio and accelerate integrated solutions for pharmaceutical and biotech customers.
-
- Buyer
- Carlyle, PAI Partners
- Target
- Theramex
- Seller
- CVC Capital Partners VI
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Type
- Buyout
Global private equity firms Carlyle and PAI Partners have agreed to acquire Theramex, a London-based specialty pharmaceuticals company focused on women's health, from CVC Capital Partners VI. The new owners plan to accelerate Theramex's international expansion and broaden its women's health product suite to drive further organic and inorganic growth.
-
March 14, 2022
- Buyer
- ANJAC Health & Beauty
- Target
- Pillar5 Pharma
- Industry
- Pharmaceuticals
- Location
- Ontario, Canada
- Type
- Buyout
French family-owned ANJAC Health & Beauty has acquired Pillar5 Pharma, a Canadian CDMO specializing in sterile ophthalmic solutions and niche solid-dose manufacturing. The deal strengthens ANJAC's presence in North America and expands its pharmaceutical and ophthalmology capabilities; Pillar5 is based in Arnprior, Ontario and has roughly 150 employees and CAD$50M in revenue.
-
- Buyer
- KELIX bio
- Target
- Pharmaceutical Institute (PHI)
- Seller
- Sedrati family (PHI founders, including Ali Sedrati)
- Industry
- Pharmaceuticals
- Location
- Morocco
- Type
- Buyout
KELIX bio, a pan-African biopharmaceutical platform, entered into a binding commitment to acquire Pharmaceutical Institute (PHI), a leading pharmaceutical manufacturer in Rabat, Morocco. The deal marks KELIX bio’s first entry into Morocco and is intended to strengthen the company’s manufacturing and distribution presence as Morocco expands universal health coverage.
-
February 28, 2022
- Buyer
- CGE Partners
- Target
- Datapharm
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Type
- Growth capital
CGE Partners has made a growth investment in Datapharm, the UK-based provider of regulatory-driven medicines information and software (including the electronic medicines compendium, emc). The investment will partner with Datapharm's management to accelerate new product development, international expansion, and support strategic acquisitions.
-
February 28, 2022
- Buyer
- Montagu
- Target
- HTL Biotechnology
- Seller
- Bridgepoint
- Industry
- Pharmaceuticals
- Location
- Brittany, France
- Type
- Buyout
Montagu, a leading private equity firm, has acquired a majority stake in HTL (HTL Biotechnology) from Bridgepoint, with minority shareholders Naxicap and Téthys Invest retaining their holdings. Montagu will support HTL's international expansion, R&D and premium product positioning and has appointed Paul Navarre as Chairman to help drive the company's next growth phase.
-
February 24, 2022
- Buyer
- Signet Healthcare Partners
- Target
- Juno Pharmaceuticals Corp.
- Industry
- Pharmaceuticals
- Location
- Quebec, Canada
- Type
- Growth capital
Signet Healthcare Partners, a New York-based healthcare growth equity firm, has completed a growth equity investment in Canadian specialty generics company Juno Pharmaceuticals Corp. Juno will use the proceeds to expand its complex and high-value generic and biosimilar portfolio and accelerate its growth and pipeline development in Canada and international markets.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.